The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Future biomarkers for MDS
Alan List
• 3 Dec 2018
The NLRP3 inflammasome initiates cell death by inducing pyroptosis, the inflammatory form of cell death. Here, Alan List, MD, of Moffitt Cancer Center, Tampa, FL, discusses the quantification of oxidized DNA, released from this cell lysis, as a biomarker of disease activity and emerging treatment response for myelodysplastic syndrome (MDS). This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
